DE2619686C2 - Verwendung eines Lysolecithins zur Tumorbehandlung - Google Patents

Verwendung eines Lysolecithins zur Tumorbehandlung

Info

Publication number
DE2619686C2
DE2619686C2 DE2619686A DE2619686A DE2619686C2 DE 2619686 C2 DE2619686 C2 DE 2619686C2 DE 2619686 A DE2619686 A DE 2619686A DE 2619686 A DE2619686 A DE 2619686A DE 2619686 C2 DE2619686 C2 DE 2619686C2
Authority
DE
Germany
Prior art keywords
tumor
lysolecithin
tumors
treatment
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2619686A
Other languages
German (de)
English (en)
Other versions
DE2619686A1 (de
Inventor
Paul Gerhard Dr. 7830 Emmendingen Munder
Otto Prof. Dr. 7808 Waldkirch Westphal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to DE2619686A priority Critical patent/DE2619686C2/de
Priority to NLAANVRAGE7704723,A priority patent/NL189672C/nl
Priority to NZ183981A priority patent/NZ183981A/xx
Priority to SE7705071A priority patent/SE7705071L/xx
Priority to IT23094/77A priority patent/IT1071329B/it
Priority to IL51988A priority patent/IL51988A/xx
Priority to IE888/77A priority patent/IE44927B1/en
Priority to AU24819/77A priority patent/AU517586B2/en
Priority to CA277,458A priority patent/CA1094455A/en
Priority to ZA00772649A priority patent/ZA772649B/xx
Priority to LU77248A priority patent/LU77248A1/xx
Priority to GB18431/77A priority patent/GB1583661A/en
Priority to BE177280A priority patent/BE854270A/xx
Priority to FR7713522A priority patent/FR2364656A1/fr
Priority to JP5194477A priority patent/JPS52134027A/ja
Publication of DE2619686A1 publication Critical patent/DE2619686A1/de
Application granted granted Critical
Publication of DE2619686C2 publication Critical patent/DE2619686C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE2619686A 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung Expired DE2619686C2 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung
NLAANVRAGE7704723,A NL189672C (nl) 1976-05-04 1977-04-29 Werkwijze voor het bereiden of vervaardigen van een farmaceutisch preparaat met anti-tumoractiviteit en werkwijze voor het bereiden van een verbinding met anti-tumoractiviteit.
SE7705071A SE7705071L (sv) 1976-05-04 1977-05-02 Antitumormedel
IT23094/77A IT1071329B (it) 1976-05-04 1977-05-02 Mezzo antitumorale
IL51988A IL51988A (en) 1976-05-04 1977-05-02 Anti-tumor agents containing lysolecithin analogues
NZ183981A NZ183981A (en) 1976-05-04 1977-05-02 Tumour antidotes containing lysolecithintype compounds
AU24819/77A AU517586B2 (en) 1976-05-04 1977-05-03 Tumor antidote
CA277,458A CA1094455A (en) 1976-05-04 1977-05-03 Tumor antidote
IE888/77A IE44927B1 (en) 1976-05-04 1977-05-03 Tumor antidote
ZA00772649A ZA772649B (en) 1976-05-04 1977-05-03 Tumor antidote
LU77248A LU77248A1 (nl) 1976-05-04 1977-05-03
GB18431/77A GB1583661A (en) 1976-05-04 1977-05-03 Tumour antidote
BE177280A BE854270A (fr) 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine
FR7713522A FR2364656A1 (fr) 1976-05-04 1977-05-04 Medicament anti-tumeur a base de compose du type lysolecithine
JP5194477A JPS52134027A (en) 1976-05-04 1977-05-04 Antiitumor agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2619686A DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Publications (2)

Publication Number Publication Date
DE2619686A1 DE2619686A1 (de) 1977-11-24
DE2619686C2 true DE2619686C2 (de) 1986-08-07

Family

ID=5977045

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2619686A Expired DE2619686C2 (de) 1976-05-04 1976-05-04 Verwendung eines Lysolecithins zur Tumorbehandlung

Country Status (15)

Country Link
JP (1) JPS52134027A (nl)
AU (1) AU517586B2 (nl)
BE (1) BE854270A (nl)
CA (1) CA1094455A (nl)
DE (1) DE2619686C2 (nl)
FR (1) FR2364656A1 (nl)
GB (1) GB1583661A (nl)
IE (1) IE44927B1 (nl)
IL (1) IL51988A (nl)
IT (1) IT1071329B (nl)
LU (1) LU77248A1 (nl)
NL (1) NL189672C (nl)
NZ (1) NZ183981A (nl)
SE (1) SE7705071L (nl)
ZA (1) ZA772649B (nl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935580A1 (de) * 1989-10-25 1991-05-02 Medmark Pharma Gmbh Pharmazeutische zubereitung zur behandlung von hiv-infektionen

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5396311A (en) * 1977-01-29 1978-08-23 Toyama Chem Co Ltd Anti-cander drugs containing lysolecithins
JPS5528955A (en) * 1978-08-24 1980-02-29 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative, its salt, their preparation, and carcinostatic agent containing the same.
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4408052A (en) * 1980-02-27 1983-10-04 Takeda Chemical Industries, Ltd. Phospholipid carbamates
US4551532A (en) * 1980-05-08 1985-11-05 Takeda Chemical Industries, Ltd. Ethylene glycol derivatives having anti-protozoan, anti-fungal and anti-tumor activity
US4444766A (en) * 1980-10-21 1984-04-24 Boehringer Mannheim Gmbh Sulfur-containing phospholipid compounds and therapeutic compositions
JPS5772914A (en) * 1980-10-22 1982-05-07 Takeda Chem Ind Ltd Antitumor agent
EP0061872B1 (en) * 1981-03-30 1985-08-07 Takeda Chemical Industries, Ltd. Ethyleneglycol derivatives, their production and use
DE3127503A1 (de) * 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3131524A1 (de) * 1981-08-08 1983-02-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung physiologischer effektoren
US4562179A (en) * 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
DE3239817A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue glycerinderivate zur synthese von phospholipiden
DE3239858A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden
EP0103877B1 (en) * 1982-09-21 1987-01-07 Fujisawa Pharmaceutical Co., Ltd. Phosphate derivatives, process for preparation thereof and pharmaceutical compositions of the same
US4710579A (en) * 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4761404A (en) * 1985-07-01 1988-08-02 Merck & Co., Inc. Phospholipid analogs useful as PAF synthesis inhibitors
EP0209239B1 (en) * 1985-07-15 1989-03-01 Takeda Chemical Industries, Ltd. 2-alkanoyloxypropane derivatives, their production and use
JPS6294A (ja) * 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
US5036152A (en) * 1988-03-10 1991-07-30 Hoechst-Roussel Pharmaceuticals Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
US4888328A (en) * 1988-03-10 1989-12-19 Hoeschst-Roussel Incorporated Alkoxycarbonylalkylphospholipids and alkylaminocarbonylalkylphospholipids
DE3906952A1 (de) * 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
DE3918082A1 (de) * 1989-06-02 1991-01-24 Max Planck Gesellschaft Mittel gegen autoimmunerkrankungen
WO1992019627A2 (en) * 1991-04-25 1992-11-12 The University Of British Columbia Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents
ES2034885B1 (es) * 1991-07-10 1994-03-01 Menarini Lab Procedimiento para la preparacion de cetoalquilglicerofosfolipidos.
DK0785773T3 (da) * 1994-10-14 2001-01-29 Liposome Co Inc Etherlipidliposomer og deres terapeutiske anvendelse
US5965159A (en) * 1996-02-16 1999-10-12 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6667053B1 (en) 1996-02-16 2003-12-23 Elan Pharmaceuticals, Inc. D and L etherlipid stereoisomers and liposomes
US5942246A (en) * 1996-02-16 1999-08-24 The Liposome Company, Inc. Etherlipid containing multiple lipid liposomes
USRE39042E1 (en) * 1996-02-16 2006-03-28 The Liposome Company, Inc. Etherlipid-containing multiple lipid liposomes
US6007839A (en) * 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US6135426A (en) * 1998-01-07 2000-10-24 Briggs And Stratton Corporation Priming system for internal combustion engines
JP5773569B2 (ja) * 2006-11-10 2015-09-02 アルファプトーゼ ゲーエムベーハーＡｌｐｈａｐｔｏｓｅ Ｇｎｂｈ 受容体リガンド模倣体を検出する方法
EP2091520B1 (en) 2006-11-10 2012-02-22 Alphaptose Gmbh Oral dosage form comprising tri-substituted glycerol compounds
EP2120873B1 (en) * 2006-12-20 2012-06-27 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
AU2007334775A1 (en) * 2006-12-20 2008-06-26 Universitatsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2033361C3 (de) * 1970-07-06 1980-02-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Acylpropandiol-(13)-phosphorsäurecholinester und Verfahren zu deren Herstellung

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935580A1 (de) * 1989-10-25 1991-05-02 Medmark Pharma Gmbh Pharmazeutische zubereitung zur behandlung von hiv-infektionen
DE3935580C2 (de) * 1989-10-25 1998-05-28 Medmark Pharma Gmbh Verwendung eines pharmazeutischen Wirkstoffes zur Behandlung von HIV-Infektionen

Also Published As

Publication number Publication date
DE2619686A1 (de) 1977-11-24
GB1583661A (en) 1981-01-28
IL51988A (en) 1981-05-20
JPS6146455B2 (nl) 1986-10-14
ZA772649B (en) 1978-04-26
NZ183981A (en) 1980-04-28
FR2364656A1 (fr) 1978-04-14
AU2481977A (en) 1978-11-09
AU517586B2 (en) 1981-08-13
IE44927B1 (en) 1982-05-19
IL51988A0 (en) 1977-07-31
SE7705071L (sv) 1977-11-05
NL7704723A (nl) 1977-11-08
LU77248A1 (nl) 1977-12-13
NL189672B (nl) 1993-01-18
JPS52134027A (en) 1977-11-09
CA1094455A (en) 1981-01-27
IT1071329B (it) 1985-04-02
NL189672C (nl) 1993-06-16
BE854270A (fr) 1977-11-04
FR2364656B1 (nl) 1980-03-07
IE44927L (en) 1977-11-04

Similar Documents

Publication Publication Date Title
DE2619686C2 (de) Verwendung eines Lysolecithins zur Tumorbehandlung
DE69217056T4 (de) Taxan-Derivate enthaltende Arzneimittel
DE2329485C3 (de) Platinkoordinationsverbindungen und ein diese Verbindungen enthaltendes Antitumormittel
DE2721171C3 (de) Vincamin-5-pyridoxalphosphat, seine Herstellung und enthaltende Zubereitungen
CH686868A5 (de) Infusionsloesung fuer die Verabreichung von Taxol.
DE3207472A1 (de) Platin-diamin-komplexe, ein verfahren zu ihrer herstellung, ein verfahren zur herstellung eines arzneimittels unter einsatz eines derartigen platin-diamin-komplexes fuer die behandlung von krebs sowie das dabei erhaltene arzneimittel
DE2707934C2 (nl)
DE2208787C3 (de) Mittel zur Behandlung von Herpes-Virusinfektionen
DE3130912A1 (de) Analgetische arzneimittelkombination
DE2609399C2 (de) 9-Desoxy-9-methylen-16,16-dimethyl-prostaglandinderivate und Verfahren zu deren Herstellung
DE102007014375A1 (de) Oleylphosphocholin
DE2145359A1 (de) Neue Phthalazindenvate
DE69735383T2 (de) Methode zur Inhibierung von HEREGULIN und seines Rezeptors sowie Verwendung zur Inhibierung von Krebszellen
DE19953517C1 (de) Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
DE2953309C2 (de) Cytostatisch wirkende Arzneimittel beziehungsweise pharmazeutische Zubereitungen
DE3786682T2 (de) ACTH-Fragmente enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Schockzuständen sowie von respiratorischen und Herz-Kreislauf-Insuffizienzen.
DE4115559A1 (de) Antitumormittel mit verminderter toxizitaet auf der basis von cytostatika und xanthogenaten
DE1518443C (de) 2-(2,6-Dimethoxyphenoxyäthyl)-aminomethyl-l,4-benzodioxan und dessen Hydrochlorid sowie Verfahren zu deren Herstellung
DE2314387A1 (de) Arzneimittel zur behandlung boesartiger neubildungen, vorzugsweise von haemoblastosen und chorionepitheliom
DE966040C (de) Haarpflegemittel
DD283931A5 (de) Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen
DE2645873C3 (de) Ajmalinderivate und ein Verfahren zu deren Herstellung
DE1792788A1 (de) Peripher vasodilatorisch wirksames arzneimittel
DE3390386T1 (de) Antitumor-Mittel, Verfahren zur Tumor-Therapie und Verwendung zur Tumor-Therapie
DE2800508C3 (de) 6,77-Dimethoxy-2-thiomorpholino-4chinazolinamin

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8181 Inventor (new situation)

Free format text: MUNDER, PAUL GERHARD, DR., 7830 EMMENDINGEN, DE WESTPHAL, OTTO, PROF. DR., 7808 WALDKIRCH, DE

D2 Grant after examination
8364 No opposition during term of opposition